1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts

MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts

Summary

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

Embolization devices including bare metal and bioactive/coated coils, aneurysm remodeling devices (stents and occlusion balloons), flow diversion devices and liquid embolic agents can be used to treat intracranial aneurysms and arteriovenous malformations (AVMs) and optimize outcomes. Low-profile stent and balloon systems can be used to revascularize plaque burdened arteries in the cerebrovasculature. Mechanical thrombectomy devices including distal and proximal devices and stent retrievers can improve recanalization rates and provide predictable outcomes in the setting of acute ischemic stroke (AIS). In addition, the next generation of access/support devices has been developed to improve navigation, trackability and flexibility as well as provide stable access, especially through tortuous anatomy.

This report focuses on the global neurovascular interventions market in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil) for treating cerebrovascular disease including intracranial aneurysms and AVMs, atherosclerotic disease, and AIS. The global neurovascular interventions market is determined for the 10 countries covered in this report and provides insight into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different device segments within the neurointerventional market. The report identifies the unmet needs in the market while providing an understanding of physicians’ perceptions and decision-making processes in using neurointerventional devices; this report also evaluates the adoption of various neurointerventional devices in the future.

Highlights

Key Questions Answered

- The neurovascular interventions market is expected to continue its growth through the forecast period. (Q).What are the primary patient segments, indications and different product offerings in the neurovascular interventions market?
- Endovascular therapy for cerebrovascular applications has seen rapid development in materials research and new techniques for treatment. (Q).What specific technologies/device segments will drive the market ? (Q).What are the future trends and drivers for growth in the market?
- Innovative technologies such as flow diverters and stent retrievers have been developed to treat challenging indications. (Q).Is flow diversion a viable alternative for patients with complex aneurysms? (Q).Will stent retrievers continue to be adopted widely in clinical practice in the future? (Q).Do we see pricing pressure in the neurointerventional devices?
- Stenting and balloon angioplasty is primarily performed in the setting of carotid artery stenosis. (Q).What is the market potential for revascularization devices? (Q).What is the market outlook for endovascular stenting for atherosclerotic disease?
- The top players in this market have developed a broad and comprehensive portfolio of neurointerventional devices for various cerebrovascular indications. (Q).What role do smaller players have in grabbing market share in the different global regions? (Q).Who are the key players in the neurovascular interventional market?

Scope

- Overview of cerebrovascular disease, including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
- Annualized total neurovascular interventions market revenue by device segment, annual cost of disease and neurointerventional devices adoption pattern and procedure data from 2011-2013 and forecast for seven years to 2020.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each region covered in the report, and implications of the neurovascular interventions market.
- Pipeline analysis: Comprehensive data split across different stages of development, emerging trends and device designs in development.
- Analysis of the current and future market competition in the global neurovascular interventions market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global neurovascular interventions market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neurovascular interventions market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific neurovascular interventions market from 2011-2020.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts
1 Table of Contents

2 Introduction 31
2.1 Catalyst 32
3 Clinical Outcomes 34
3.1 Disease Management 34
3.1.1 Intracranial Aneurysms 34
3.1.2 Intracranial Arteriovenous Malformations 35
3.1.3 Dural Arteriovenous Fistulas 36
3.1.4 Intracranial and Extracranial Atherosclerotic Disease 36
3.1.5 Stroke 37
3.2 Treatment Modalities 38
3.2.1 Overview 38
3.2.2 Medical/Chemical Therapy 39
3.2.3 Surgical Therapy 40
3.2.4 Endovascular Therapy 42
4 Industry Overview 53
4.1 Overview 53
4.2 Procedure Trends 53
4.2.1 Intracranial Aneurysms 53
4.2.2 Intracranial Arteriovenous Malformations 59
4.2.3 Atherosclerotic Disease 60
4.2.4 Acute Ischemic Stroke 65
4.3 Market Access 68
4.3.1 Regulatory Process 70
4.3.2 Physician Perception and Decision Making Process 76
4.3.3 Variations in Clinical Practice 82
4.3.4 Lack of Clinical Data 82
4.3.5 Regional-Level Control 83
4.3.6 Cost-Considerations 84
4.3.7 Reimbursement Trends 89
4.4 Regulatory Issues/Recalls 98
4.4.1 Regulatory Issues 98
4.4.2 Product Recalls 99
4.5 Mergers and Acquisitions/Key Partnerships 99
4.5.1 Covidien and Nfocus Neuromedical 99
4.5.2 Stryker Corporation and Surpass Medical 100
4.5.3 Covidien and MindFrame 100
4.5.4 Covidien and Reverse Medical Corporation 100
4.5.5 Stryker Corporation and Boston Scientific Neurovascular 101
4.5.6 Stryker Corporation and Concentric Medical 101
4.5.7 Covidien and ev3 102
4.5.8 Medtronic and Invatec 102
4.5.9 Johnson and Johnson and Micrus Endovascular 102
4.5.10 ev3 and Chestnut Medical Technologies 103
4.5.11 Boston Scientific Corporation and Guidant Corporation 103
4.6 Economic Impact 104
4.6.1 Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations 104
4.6.2 Economic Impact of Stroke 105
4.6.3 Treatment Costs of Cerebrovascular Disease 106
5 Unmet Needs 110
5.1 Overview 110
5.2 Need for Practice, Performance, and Physician Training Guidelines 110
5.3 Lack of Clinical Data 111
5.4 Improve Management of Acute Ischemic Stroke 112
5.5 Address Complications of Surgical Therapy 114
5.6 Addressing the Challenges of Surgical Clipping 114
5.7 Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms 115
5.8 Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes 116
5.9 Difficulty in Treating Intracranial Arteriovenous Malformations 117
5.10 Eliminating Mechanisms of Failure with Balloon Angioplasty 118
5.11 Addressing Challenges of Neurovascular Stenting 119
5.11.1 Risk of Post-Procedural Complications 119
5.11.2 In-Stent Restenosis 120
5.11.3 Stent Navigation 120
5.12 Complications of Dual Antiplatelet Therapy 120
5.13 Need to Improve Medical Therapy 121
5.14 Improve Ease of Access 122
6 Market Opportunity Analysis 123
6.1 Neurovascular Interventions Market 123
6.2 Improve Neurointerventional Device Design 123
6.3 Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations 125
6.3.1 Intracranial Aneurysms 125
6.3.2 Intracranial Arteriovenous Malformations 126
6.4 Target Challenging Patient Populations 127
6.5 Optimize Care for Acute Ischemic Stroke Patients 127
6.6 Development of Drug-Eluting Devices 129
6.7 Emerging Markets 129
7 Market Drivers and Barriers 131
7.1 Market Drivers 131
7.1.1 Rising Prevalence of Disease 132
7.1.2 Improved Clinical Outcomes with Endovascular Coiling 133
7.1.3 Remodeling Techniques with Stent and Balloon-Assisted Coiling 134
7.1.4 Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms 136
7.1.5 Alternative Non-Coiling Embolization Devices for Aneurysm Treatment 137
7.1.6 Endovascular Embolization of Intracranial Arteriovenous Malformations 138
7.1.7 Imaging Assessment for Intracranial Arteriovenous Malformation Treatment 139
7.1.8 Stenting for Carotid Atherosclerotic Disease 139
7.1.9 Low-Profile Stent Systems 140
7.1.10 Improved Recanalization Rates with Mechanical Thrombectomy Devices 141
7.1.11 Cost Savings 143
7.1.12 Availability of Long-Term and Cost-Effective Data 143
7.2 Market Barriers 144
7.2.1 Complications of Neurointerventional Procedures and Devices 144
7.2.2 Lack of Clinical Data 150
7.2.3 High Cost of Treatment 150
7.2.4 Lack of Reimbursement 152
7.2.5 Lack of Superiority of Bioactive/Coated Coils 153
7.2.6 Alternative Technologies for Stroke Therapy 154
7.2.7 Regulatory Challenges: US Food and Drug Administration and European Conformity Mark 154
7.2.8 Healthcare Cost-Cutting and Reimbursement 155
7.2.9 Availability of Venture Capital 156
7.2.10 Medical Device Excise Tax 157
8 Competitive Assessment 158
8.1 Overview 158
8.2 Global Market Share 158
8.3 Marketed Products 159
8.3.1 Aachen Resonance 159
8.3.2 Abbott Vascular 161
8.3.3 Acandis 163
8.3.4 B. Braun 166
8.3.5 BALT Extrusion 167
8.3.6 Blockade Medical 172
8.3.7 Boston Scientific Corporation 173
8.3.8 Contego Medical 175
8.3.9 Cook Medical 175
8.3.10 Covidien 176
8.3.11 Gardia Medical 183
8.3.12 Gore Medical 184
8.3.13 InspireMD 186
8.3.14 ITGI Medical 187
8.3.15 Johnson and Johnson 188
8.3.16 Medikit 194
8.3.17 Medtronic 196
8.3.18 Merlin MD 199
8.3.19 MicroPort Scientific Corporation 200
8.3.20 Minvasys 202
8.3.21 Neuravi 203
8.3.22 Optimed 204
8.3.23 Penumbra 206
8.3.24 Phenox GmbH 209
8.3.25 Reverse Medical 211
8.3.26 Sequent Medical 213
8.3.27 Stryker Neurovascular Intervention 215
8.3.28 Terumo Corporation 222
8.3.29 Valor Medical 230
9 Pipeline Assessment 232
9.1 Overview 232
9.2 Pipeline by Stage of Development 232
9.3 Product Profiles 234
9.3.1 Aneurysm Occlusion Saddle 234
9.3.2 Ballstent Microcatheter 235
9.3.3 Blood Clot Removing Device 235
9.3.4 EKOS' EkoSonic Small Vessel Endovascular System 236
9.3.5 Flow-Diverting Thin-Film Nitinol Covered Stent 236
9.3.6 Ischemic Stroke System 237
9.3.7 Janjua Aneurysm Net 238
9.3.8 Multilayer Aneurysm Repair System 238
9.3.9 NAVIMAX 239
9.3.10 Palmaz Scientific Stents 240
9.3.11 Silk Road System 241
9.3.12 Transcranial Thrombectomy Catheter 242
10 Clinical Trial Analysis 243
10.1 Overview 243
10.2 Clinical Trials to Watch 244
10.2.1 Embolization 244
10.2.2 Flow Diversion 246
10.2.3 Revascularization 249
10.2.4 Mechanical Thrombectomy 250
11 Current and Future Players 253
11.1 Overview 253
11.2 Trends in Corporate Strategy 253
11.3 Company Profiles 255
11.3.1 BALT Extrusion 255
11.3.2 Covidien 258
11.3.3 Johnson and Johnson 261
11.3.4 Penumbra 266
11.3.5 Stryker Corporation 269
11.3.6 Terumo Corporation 271
11.3.7 Abbott Vascular 275
11.3.8 Boston Scientific Corporation 277
11.3.9 Cook Medical 279
11.3.10 Gore Medical 281
11.3.11 Medtronic 283
11.3.12 Aachen Resonance 285
11.3.13 Acandis 287
11.3.14 B. Braun 290
11.3.15 Blockade Medical 291
11.3.16 Contego Medical 293
11.3.17 Gardia Medical 294
11.3.18 InspireMD 296
11.3.19 ITGI Medical 298
11.3.20 Medikit 299
11.3.21 Merlin MD 300
11.3.22 MicroPort Scientific Corporation 302
11.3.23 Minvasys 303
11.3.24 Neuravi 305
11.3.25 Optimed 306
11.3.26 Phenox GmBH 308
11.3.27 Reverse Medical 309
11.3.28 Sequent Medical 311
11.3.29 Valor Medical 312
11.3.30 Other Companies 315
12 Market Outlooks 317
12.1 By Market Segment 317
12.1.1 Embolization Device Market 319
12.1.2 Revascularization Device Market 323
12.1.3 Mechanical Thrombectomy Device Market 326
12.1.4 Access/Support Device Market 329
12.2 By Geography 331
12.2.1 Global Overview 331
12.2.2 United States 332
12.2.3 The Five European Union Markets 339
12.2.4 The Asia-Pacific Region 367
12.2.5 South America 386
13 Appendix 393
13.1 Bibliography 393
13.2 Abbreviations 417
13.3 Report Methodology 423
13.3.1 Overview 423
13.3.2 Coverage 423
13.3.3 Secondary Research 423
13.4 Physicians and Specialists Included in this Study 424
13.4.1 Vivek Gupta, MD 424
13.4.2 Zsolt Kulscár, MD, PhD 424
13.4.3 Salvatore Mangiafico, MD 424
13.4.4 Thanh Nguyen, MD, FRCPc 424
13.4.5 Eduardo Wajnberg, MD 425
13.4.6 Phil White, MD 425
13.4.7 Osama O Zaidat, MD, MS, FAAN, FAHA 425
13.5 Primary Research 425
13.5.1 Primary Research - Key Opinion Leader Interviews 425
13.5.2 Expert Panel Validation 426
13.6 Forecasting Methodology 427
13.7 About the Authors 429
13.7.1 Analysts 429
13.7.2 Global Head of Healthcare 430
13.8 About MediPoint 431
13.9 About GlobalData 431
13.10 Disclaimer 431

1.1 List of Tables

Table 1: Complications of Cerebral Artery Bypass Surgery 41
Table 2: Types of Cerebral Embolic Protection Devices 49
Table 3: Medicare National Average of Inpatient Hospital Payment for Neurovascular Interventions, 2013-2014 90
Table 4: Reimbursement Classification of Medical Devices in Japan 95
Table 5: US Mean Hospital Costs* for Treating Cerebrovascular Disease, 2011-2020 ($US) 106
Table 6: Aachen Resonance Neurovascular Intervention Marketed Product 159
Table 7: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 161
Table 8: Abbott Vascular Neurovascular Intervention Marketed Products 162
Table 9: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 163
Table 10: Acandis Neurovascular Intervention Marketed Products 164
Table 11: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 165
Table 12: B. Braun Neurovascular Intervention Marketed Product 166
Table 13: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 166
Table 14: BALT Extrusion Neurovascular Intervention Marketed Products 168
Table 15: BALT Extrusion Neurovascular Intervention Marketed Access Products 170
Table 16: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 171
Table 17: Blockade Medical Neurovascular Intervention Marketed Product 172
Table 18: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 173
Table 19: Boston Scientific Neurovascular Intervention Marketed Products 174
Table 20: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 174
Table 21: Contego Medical Neurovascular Intervention Marketed Product 175
Table 22: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 175
Table 23: Cook Medical Neurovascular Intervention Marketed Products 176
Table 24: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 176
Table 25: Covidien Neurovascular Interventional Marketed Products 178
Table 26: Covidien Neurovascular Intervention Marketed Access Products 181
Table 27: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 182
Table 28: Gardia Medical Neurovascular Intervention Marketed Product 183
Table 29: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 184
Table 30: Gore Medical Neurovascular Intervention Marketed Products 185
Table 31: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 185
Table 32: InspireMD Neurovascular Intervention Marketed Product 186
Table 33: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 186
Table 34: ITGI Medical Neurovascular Intervention Marketed Product 187
Table 35: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 188
Table 36: Codman Neurovascular Marketed Embolization Products 189
Table 37: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products 191
Table 38: Codman Neurovascular's (Codman and Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 192
Table 39: Cordis Corporation Marketed Neurointerventional Products 193
Table 40: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 194
Table 41: Medikit Neurovascular Intervention Marketed Products 195
Table 42: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 196
Table 43: Medtronic Neurovascular Intervention Marketed Products 197
Table 44: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 198
Table 45: Merlin MD Neurovascular Intervention Marketed Product 199
Table 46: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 200
Table 47: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products 201
Table 48: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 202
Table 49: Minvasys Neurovascular Intervention Marketed Product 203
Table 50: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 203
Table 51: Neuravi Neurovascular Intervention Marketed Product 204
Table 52: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 204
Table 53: Optimed Neurovascular Intervention Marketed Products 205
Table 54: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 205
Table 55: Penumbra Neurovascular Intervention Marketed Products 206
Table 56: Penumbra Marketed Neurovascular Access Products 208
Table 57: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 209
Table 58: Phenox GmbH Neurovascular Intervention Marketed Products 210
Table 59: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 211
Table 60: Reverse Medical Neurovascular Intervention Marketed Products 212
Table 61: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 213
Table 62: Sequent Medical Neurovascular Intervention Marketed Products 214
Table 63: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 215
Table 64: Stryker Neurovascular Intervention Marketed Products 217
Table 65: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products 219
Table 66: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 221
Table 67: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products 223
Table 68: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014 224
Table 69: MicroVention Neurovascular Intervention Marketed Products 226
Table 70: MicroVention Marketed Neurovascular Access Products 228
Table 71: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014 229
Table 72: Valor Medical Neurovascular Intervention Marketed Products 230
Table 73: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 231
Table 74: Global Neurovascular Interventions Pipeline Products 234
Table 75: Aneurysm Occlusion Saddle SWOT Analysis, 2014 235
Table 76: EKOS EkoSonic SV System SWOT Analysis, 2014 236
Table 77: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014 237
Table 78: Janjua Aneurysm Net SWOT Analysis, 2014 238
Table 79: Multilayer Aneurysm Repair System SWOT Analysis, 2014 239
Table 80: NAVIMAX SWOT Analysis, 2014 240
Table 81: Palmaz Scientific Stents SWOT Analysis, 2014 241
Table 82: Silk Road System SWOT Analysis, 2014 242
Table 83: BALT Extrusion Company Profile 256
Table 84: BALT Extrusion Neurovascular Intervention Marketed Products 257
Table 85: BALT Extrusion SWOT Analysis, 2014 258
Table 86: Covidien Company Profile 259
Table 87: Covidien Neurovascular Intervention Marketed Products 260
Table 88: Covidien SWOT Analysis, 2014 261
Table 89: Codman and Shurtleff Company Profile 262
Table 90: Codman and Shurtleff Neurovascular Intervention Marketed Products 263
Table 91: Codman and Shurtleff SWOT Analysis, 2014 264
Table 92: Cordis Corporation Company Profile 264
Table 93: Cordis Corporation Neurovascular Intervention Marketed Products 265
Table 94: Cordis Corporation SWOT Analysis, 2014 266
Table 95: Penumbra Company Profile 266
Table 96: Penumbra Neurovascular Intervention Marketed Products 268
Table 97: Penumbra SWOT Analysis, 2014 268
Table 98: Stryker Corporation Company Profile 269
Table 99: Stryker Corporation Neurovascular Intervention Marketed Products 270
Table 100: Stryker Corporation SWOT Analysis, 2014 271
Table 101: Terumo Corporation Company Profile 272
Table 102: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products 273
Table 103: MicroVention Neurovascular Intervention Marketed Products 274
Table 104: Terumo Corporation SWOT Analysis, 2014 275
Table 105: Abbott Vascular Company Profile 275
Table 106: Abbott Vascular Neurovascular Intervention Marketed Products 276
Table 107: Abbott Vascular SWOT Analysis, 2014 277
Table 108: Boston Scientific Corporation Company Profile 278
Table 109: Boston Scientific Neurovascular Intervention Marketed Products 278
Table 110: Boston Scientific Corporation SWOT Analysis, 2014 279
Table 111: Cook Medical Company Profile 279
Table 112: Cook Medical Neurovascular Intervention Marketed Products 280
Table 113: Cook Medical SWOT Analysis, 2014 281
Table 114: Gore Medical Company Profile 282
Table 115: Gore Medical Neurovascular Intervention Marketed Products 282
Table 116: Gore Medical SWOT Analysis, 2014 283
Table 117: Medtronic Company Profile 284
Table 118: Medtronic Neurovascular Intervention Marketed Products 285
Table 119: Medtronic SWOT Analysis, 2014 285
Table 120: Aachen Resonance Company Profile 286
Table 121: Aachen Resonance Neurovascular Intervention Marketed Product 287
Table 122: Aachen Resonance SWOT Analysis, 2014 287
Table 123: Acandis Company Profile 288
Table 124: Acandis Neurovascular Intervention Marketed Products 289
Table 125: Acandis SWOT Analysis, 2014 289
Table 126: B. Braun Company Profile 290
Table 127: B. Braun Neurovascular Intervention Marketed Product 291
Table 128: B. Braun SWOT Analysis, 2014 291
Table 129: Blockade Medical Company Profile 292
Table 130: Blockade Medical Neurovascular Intervention Marketed Product 292
Table 131: Blockade Medical SWOT Analysis, 2014 293
Table 132: Contego Medical Company Profile 293
Table 133: Contego Medical Neurovascular Intervention Marketed Product 294
Table 134: Contego Medical SWOT Analysis, 2014 294
Table 135: Gardia Medical Company Profile 295
Table 136: Gardia Medical Neurovascular Intervention Marketed Product 295
Table 137: Gardia Medical SWOT Analysis, 2014 296
Table 138: InspireMD Company Profile 297
Table 139: InspireMD Neurovascular Intervention Marketed Product 297
Table 140: InspireMD SWOT Analysis, 2014 297
Table 141: ITGI Medical Company Profile 298
Table 142: ITGI Medical Neurovascular Intervention Marketed Product 298
Table 143: ITGI Medical SWOT Analysis, 2014 299
Table 144: Medikit Company Profile 299
Table 145: Medikit Neurovascular Intervention Marketed Products 300
Table 146: Medikit SWOT Analysis, 2014 300
Table 147: Merlin MD Company Profile 301
Table 148: Merlin MD Neurovascular Intervention Marketed Product 301
Table 149: Merlin MD SWOT Analysis, 2014 301
Table 150: MicroPort Scientific Corporation Company Profile 302
Table 151: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products 302
Table 152: MicroPort Scientific Corporation SWOT Analysis, 2014 303
Table 153: Minvasys Company Profile 304
Table 154: Minvasys Neurovascular Intervention Marketed Product 304
Table 155: Minvasys SWOT Analysis, 2014 304
Table 156: Neuravi Company Profile 305
Table 157: Neuravi Neurovascular Intervention Marketed Product 305
Table 158: Neuravi SWOT Analysis, 2014 306
Table 159: Optimed Company Profile 307
Table 160: Optimed Neurovascular Intervention Marketed Products 307
Table 161: Optimed SWOT Analysis, 2014 307
Table 162: Phenox GmBH Company Profile 308
Table 163: Phenox GmbH Neurovascular Intervention Marketed Products 309
Table 164: Phenox GmBH SWOT Analysis, 2014 309
Table 165: Reverse Medical Company Profile 310
Table 166: Reverse Medical Neurovascular Intervention Marketed Products 310
Table 167: Reverse Medical SWOT Analysis, 2014 311
Table 168: Sequent Medical Company Profile 311
Table 169: Sequent Medical Neurovascular Intervention Marketed Products 312
Table 170: Sequent Medical SWOT Analysis, 2014 312
Table 171: Valor Medical Company Profile 313
Table 172: Valor Medical Neurovascular Intervention Marketed Products 313
Table 173: Valor Medical SWOT Analysis, 2014 314
Table 174: Other Companies in the Neurovascular Intervention Market, 2014 315
Table 175: Global Embolization Device Market ($m) Forecast, 2011-2020 319
Table 176: Global Revascularization Device Market ($m) Forecast, 2011-2020 323
Table 177: Global Mechanical Thrombectomy Device Market ($m) Forecast, 2011-2020 326
Table 178: Global Access/Support Device Market ($m) Forecast, 2011-2020 329
Table 179: Neurovascular Interventions Market Sales ($m) Forecast for the US, 2011-2020 333
Table 180: Neurovascular Interventions Market Sales ($m) Forecast for France, 2011-2020 340
Table 181: Neurovascular Interventions Market Sales ($m) Forecast for Germany, 2011-2020 345
Table 182: Neurovascular Interventions Market Sales ($m) Forecast for Italy, 2011-2020 351
Table 183: Neurovascular Interventions Market Sales ($m) Forecast for Spain, 2011-2020 356
Table 184: Neurovascular Interventions Market Sales ($m) Forecast for the UK, 2011-2020 362
Table 185: Neurovascular Interventions Market Sales ($m) Forecast for Japan, 2011-2020 368
Table 186: Neurovascular Interventions Market Sales ($m) Forecast for China, 2011-2020 374
Table 187: Neurovascular Interventions Market Sales ($m) Forecast for India, 2011-2020 380
Table 188: Neurovascular Interventions Market Sales ($m) Forecast for Brazil, 2011-2020 387

1.2 List of Figures
Figure 1: Treatment Modalities - Neurovascular Interventions 39
Figure 2: Types of Stents Used for Neurovascular Interventions 48
Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, US, 2011-2020 54
Figure 4: Embolization Procedure Volume for Treating Intracranial Aneurysms, 5EU, 2011-2020 56
Figure 5: Embolization Procedure Volume for Treating Intracranial Aneurysms, APAC, 2011-2020 57
Figure 6: Embolization Procedure Volume for Treating Intracranial Aneurysms, South America, 2011-2020 58
Figure 7: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, Global, 2011-2020 60
Figure 8: Revascularization Procedure Volume for Treating Atherosclerotic Disease, US, 2011-2020 61
Figure 9: Revascularization Procedure Volume for Treating Atherosclerotic Disease, 5EU, 2011-2020 62
Figure 10: Revascularization Procedure Volume for Treating Atherosclerotic Disease, APAC, 2011-2020 63
Figure 11: Revascularization Procedure Volume for Treating Atherosclerotic Disease, South America, 2011-2020 64
Figure 12: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, US, 2011-2020 65
Figure 13: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, 5EU, 2011-2020 66
Figure 14: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, APAC, 2011-2020 67
Figure 15: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, South America, 2011-2020 68
Figure 16: US Mean Hospital Costs* for Treating Intracranial Aneurysms and Arteriovenous Malformations, 2011-2020 ($US) 107
Figure 17: US Mean Hospital Costs* for Treating Extracranial and Intracranial Atherosclerotic Disease, 2011-2020 ($US) 108
Figure 18: US Mean Hospital Costs* for Treating Stroke, 2011-2020 ($US) 109
Figure 19: Global Neurointerventional Market Distribution, 2013 158
Figure 20: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014 233
Figure 21: Global Neurovascular Interventions Market ($bn) for Treating Cerebrovascular Disease, 2011-2020 317
Figure 22: Distribution of Percentage of Patients Treated for Cerebrovascular Disease, Global, 2013 318
Figure 23: Global Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 320
Figure 24: Global Embolization Device Market Distribution, 2013 and 2020 321
Figure 25: Global Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 324
Figure 26: Global Revascularization Device Market Distribution, 2013 and 2020 325
Figure 27: Global Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 327
Figure 28: Global Mechanical Thrombectomy Device Market Distribution, 2013 and 2020 329
Figure 29: Global Access/Support Device Market ($m) for Cerebrovascular Applications, 2011-2020 330
Figure 30: Global Access/Support Device Market Distribution, 2013 and 2020 331
Figure 31: Global Neurovascular Interventions Market Revenue ($bn), 2013 and 2020 332
Figure 32: US Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 334
Figure 33: US Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 336
Figure 34: US Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 337
Figure 35: US Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 338
Figure 36: US Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 339
Figure 37: French Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 340
Figure 38: French Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 341
Figure 39: French Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 342
Figure 40: French Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 343
Figure 41: French Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 344
Figure 42: German Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 345
Figure 43: German Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 347
Figure 44: German Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 348
Figure 45: German Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 349
Figure 46: German Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 350
Figure 47: Italian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 351
Figure 48: Italian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 352
Figure 49: Italian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 353
Figure 50: Italian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 354
Figure 51: Italian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 355
Figure 52: Spanish Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 357
Figure 53: Spanish Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 358
Figure 54: Spanish Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 359
Figure 55: Spanish Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 360
Figure 56: Spanish Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 361
Figure 57: UK Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 362
Figure 58: UK Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 364
Figure 59: UK Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 365
Figure 60: UK Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 366
Figure 61: UK Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 367
Figure 62: Japanese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 369
Figure 63: Japanese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 370
Figure 64: Japanese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 371
Figure 65: Japanese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 372
Figure 66: Japanese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 373
Figure 67: Chinese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 375
Figure 68: Chinese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 376
Figure 69: Chinese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 377
Figure 70: Chinese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 378
Figure 71: Chinese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 379
Figure 72: Indian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 381
Figure 73: Indian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 383
Figure 74: Indian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 384
Figure 75: Indian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 385
Figure 76: Indian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 386
Figure 77: Brazilian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 388
Figure 78: Brazilian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 389
Figure 79: Brazilian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 390
Figure 80: Brazilian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 391
Figure 81: Brazilian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 392

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.